<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEXAMETHASONE SODIUM PHOSPHATE - dexamethasone sodium phosphate injection, solution </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>Dexamethasone Sodium Phosphate Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Dexamethasone sodium phosphate is a water-soluble inorganic ester of dexamethasone.  It occurs as a white or slightly yellow crystalline powder, is odorless or has a slight odor of alcohol, is exceedingly hygroscopic and is freely soluble in water.  </p>
<p>Dexamethasone sodium phosphate is an adrenocortical steroid anti-inflammatory drug.  </p>
<p>Chemically, dexamethasone sodium phosphate is 9-Fluoro-11ß,17,21-trihydroxy-16α-methylpregna-1, 4-diene-3,20-dione 21-(dihydrogen phosphate) disodium salt and has the following structural formula:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=685c33e5-c6e0-4717-b3bb-4c2cd0fcb063&amp;name=MM1.jpg"> </p>
<p>Dexamethasone Sodium Phosphate Injection, USP is a sterile solution of dexamethasone sodium phosphate in Water for Injection for intravenous (IV), intramuscular (IM), intra-articular, soft-tissue or intralesional use.  </p>
<p>Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant; Water for Injection q.s.  Citric acid and/or sodium hydroxide may have been added for pH adjustment (7.0-8.5).  Air in the container is displaced by nitrogen.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Dexamethasone sodium phosphate has a rapid onset but short duration of action when compared with less soluble preparations.  Because of this, it is suitable for the treatment of acute disorders responsive to adrenocortical steroid therapy.  </p>
<p>Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.  Their synthetic analogs, including dexamethasone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. </p>
<p> Glucocorticoids cause profound and varied metabolic effects.  In addition, they modify the body’s immune responses to diverse stimuli.  </p>
<p>At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p><span class="Italics"><span class="Emphasis">Intravenous or Intramuscular Injection</span></span></p>
<p>When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:</p>
<p>• <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></p>
<p>     Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)</p>
<p>     Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)</p>
<p>     Preoperatively, and in the event of serious <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or illness, in patients with known <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or when adrenocortical reserve is doubtful</p>
<p>     <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span> unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected</p>
<p>     Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></p>
<p>     Nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> associated with cancer</p>
<p>• Rheumatic Disorders</p>
<p>     As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:</p>
<p>     Post-traumatic <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low-dose maintenance therapy)</p>
<p>     Acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> </p>
<p>     <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span></p>
<p>     Acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span></p>
<p>     Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">Psoriatic arthritis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span></p>
<p>• Collagen Diseases</p>
<p>     During an exacerbation or as maintenance therapy in selected cases of:</p>
<p>     <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span></p>
<p>     Acute rheumatic carditis</p>
<p>• Dermatologic Diseases</p>
<p>     <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">Pemphigus</span></p>
<p>     Severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>)</p>
<p>     <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis</p>
<p>     Severe <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span></p>
<p>     Severe <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis fungoides</span></p>
<p>• Allergic States</p>
<p>     Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:</p>
<p>     Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span></p>
<p>     Seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span> reactions</p>
<p>     Urticarial <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">transfusion reactions</span></p>
<p>     Acute noninfectious <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> (epinephrine is the drug of first choice)</p>
<p>• Ophthalmic Diseases</p>
<p>     Severe acute and chronic allergic and inflammatory processes involving the eye, such as:</p>
<p>     <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> ophthalmicus</p>
<p>     <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span>, <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">Chorioretinitis</span></p>
<p>     Diffuse posterior <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and choroiditis</p>
<p>     <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span></p>
<p>     Sympathetic ophthalmia</p>
<p>     Anterior segment <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">Allergic conjunctivitis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></p>
<p>     Allergic corneal marginal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span></p>
<p>• Gastrointestinal Diseases</p>
<p>     To tide the patient over a critical period of the disease in:</p>
<p>     <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span> (Systemic therapy)</p>
<p>     <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">Regional enteritis</span> (Systemic therapy)</p>
<p>• Respiratory Diseases</p>
<p>     Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span></p>
<p>     Berylliosis</p>
<p>     Fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means</p>
<p>     <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonitis</span></p>
<p>• Hematologic Disorders</p>
<p>     Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in adults (IV only; IM administration is contraindicated)</p>
<p>     Secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in adults</p>
<p>     Erythroblastopenia (RBC <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</p>
<p>     Congenital (erythroid) <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span></p>
<p>• Neoplastic Diseases</p>
<p>     For palliative management of:</p>
<p>     <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in adults</p>
<p>     <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute leukemia</span> of childhood</p>
<p>• Edematous States</p>
<p>     To induce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, of the idiopathic type, or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span></p>
<p>• Miscellaneous</p>
<p>     Tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy</p>
<p>     Trichinosis with neurologic or myocardial involvement</p>
<p>• Diagnostic testing of adrenocortical hyperfunction</p>
<p>• <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral Edema</span> associated with primary or metastatic <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span>, craniotomy, or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>.</p>
<p>     Use in <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy.</p>
<p>
 
</p>
<p></p>
<p>     As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:</p>
<p>     <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span></p>
<p>     Acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span></p>
<p>     Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span></p>
<p>     Acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span></p>
<p>     Post-traumatic <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></p>
<p>
 
</p>
<p></p>
<p>     Keloids</p>
<p>     Localized hypertrophic, infiltrated, inflammatory lesions of: <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, psoriatic plaques, <span class="product-label-link" type="condition" conceptid="4277253" conceptname="Granuloma annulare">granuloma annulare</span> and lichen simplex chronicus (<span class="product-label-link" type="condition" conceptid="4148920" conceptname="Neurodermatitis">neurodermatitis</span>)</p>
<p>     <span class="product-label-link" type="condition" conceptid="4066824" conceptname="Discoid lupus erythematosus">Discoid lupus erythematosus</span></p>
<p>     Necrobiosis lipoidica diabeticorum</p>
<p>     <span class="product-label-link" type="condition" conceptid="141933" conceptname="Alopecia areata">Alopecia areata</span></p>
<p>     May also be useful in cystic tumors of an aponeurosis or tendon (ganglia)</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (see <span class="Bold"><span class="Emphasis"><a href="#e1fe72ea-c1c2-4505-a680-6a0dbf0004e0">WARNINGS</a></span></span> regarding amphotericin B).  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product, including sulfites (see <span class="Bold"><span class="Emphasis"><a href="#e1fe72ea-c1c2-4505-a680-6a0dbf0004e0">WARNINGS</a></span></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>Because rare instances of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to any drug.  Anaphylactoid and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported for dexamethasone sodium phosphate (see <span class="Bold"><span class="Emphasis"><a href="#b89c1923-3c00-4b70-8697-70dcb2ba36d7">ADVERSE REACTIONS</a></span></span>).</p>
<p>Dexamethasone sodium phosphate injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people.</p>
<p>Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore, should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed to control drug reactions due to amphotericin B.   Moreover, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive failure.</p>
<p>In patients on corticosteroid therapy subjected to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.</p>
<p>Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage.  This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.  If the patient is receiving steroids already, dosage may have to be increased.  Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may appear during their use.  There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used.  Moreover, corticosteroids may affect the nitrobluetetrazolium test for <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> and produce false negative results.</p>
<p>In <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>, a double-blind trial has shown that the use of corticosteroids is associated with prolongation of <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and a higher incidence of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.</p>
<p>Corticosteroids may activate latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>.  Therefore, it is recommended that latent or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses.</p>
<p>Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium.  These effects are less likely to occur with the synthetic derivatives except when used in large doses.  Dietary salt restriction and potassium supplementation may be necessary.  All corticosteroids increase calcium excretion.</p>
<p>Administration of live virus vaccines, including <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span>, is contraindicated in individuals receiving immunosuppressive doses of corticosteroids.  If inactivated viral or bacterial vaccines are administered to individuals receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained.  However, immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease.</p>
<p>Persons who are on drugs which suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy individuals.  <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids.  In such children or adults who have not had these diseases, particular care should be taken to avoid exposure.  How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known.  The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.  If exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated.  If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated.  (See the respective package inserts for complete VZIG and IG prescribing information).  If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents may be considered.</p>
<p>The use of dexamethasone sodium phosphate in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur.  During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Emphasis">T</span></span><span class="Italics"><span class="Emphasis">eratogenic Effects: Pregnancy Category C–</span></span></p>
<p>Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus.  Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
<p>Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects.  Mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>This product, like many other steroid formulations, is sensitive to heat.  Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial.</p>
<p>Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the <span class="product-label-link" type="condition" conceptid="4224791" conceptname="Steroid withdrawal syndrome">corticosteroid withdrawal syndrome</span> including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.  This may occur in patients even without evidence of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>.</p>
<p>There is an enhanced effect of corticosteroids in patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and in those with cirrhosis.</p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes simplex for <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span> of <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>.</p>
<p>The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations.  Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
<p>Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.</p>
<p>Steroids should be used with caution in nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, also in <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.  Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients receiving large doses of corticosteroids may be minimal or absent.  <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">Fat embolism</span> has been reported as a possible complication of <span class="product-label-link" type="condition" conceptid="195212" conceptname="Hypercortisolism">hypercortisonism</span>.</p>
<p>When large doses are given, some authorities advise that antacids be administered between meals to help to prevent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
<p>Growth and development of infants and children on prolonged corticosteroid therapy should be carefully followed.</p>
<p>Steroids may increase or decrease motility and number of spermatozoa in some patients.</p>
<p>Phenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic clearance of corticosteroids resulting in decreased blood levels and lessened physiologic activity, thus requiring adjustment in corticosteroid dosage.  These interactions may interfere with <span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression tests</span> which should be interpreted with caution during administration of these drugs.</p>
<p>False negative results in the <span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression test</span> (DST) in patients being treated with indomethacin have been reported.  Thus, results of the DST should be interpreted with caution in these patients.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be checked frequently in patients who are receiving corticosteroids and coumarin anticoagulants at the same time because of reports that corticosteroids have altered the response to these anticoagulants.  Studies have shown that the usual effect produced by adding corticosteroids is inhibition of response to coumarins, although there have been some conflicting reports of potentiation not substantiated by studies.</p>
<p>When corticosteroids are administered concomitantly with potassium-depleting diuretics, patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>Intra-articular injection of a corticosteroid may produce systemic as well as local effects.</p>
<p>Appropriate examination of any joint fluid present is necessary to exclude a septic process.</p>
<p>A marked increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> accompanied by <span class="product-label-link" type="condition" conceptid="4200520" conceptname="Neck swelling">local swelling</span>, further restriction of joint motion, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> is suggestive of <span class="product-label-link" type="condition" conceptid="80482" conceptname="Suppurative arthritis">septic arthritis</span>.  If this complication occurs and the diagnosis of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> is confirmed, appropriate antimicrobial therapy should be instituted.</p>
<p>Injection of a steroid into an infected site is to be avoided.</p>
<p>Corticosteroids should not be injected into unstable joints.</p>
<p>Patients should be impressed strongly with the importance of not overusing joints in which symptomatic benefit has been obtained as long as the inflammatory process remains active.</p>
<p>Frequent intra-articular injection may result in damage to joint tissues. </p>
<p> The slower rate of absorption by intramuscular administration should be recognized.</p>
<p>
 
</p>
<p></p>
<p>Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>.  Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>:</p>
<p>     <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Sodium retention</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients</p>
<p>     Potassium loss</p>
<p>     <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">Hypokalemic alkalosis</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p>Musculoskeletal:</p>
<p>     <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">Steroid myopathy</span></p>
<p>     Loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></p>
<p>     Pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones</p>
<p>     Vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads</p>
<p>     <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span></p>
<p>Gastrointestinal:</p>
<p>     <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> with possible subsequent perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></p>
<p>     Perforation of the small and large bowel, particularly in patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></p>
<p>     Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span></p>
<p>     Ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span></p>
<p>Dermatologic:</p>
<p>     Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing</p>
<p>     Thin fragile skin</p>
<p>     <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p>
<p>     Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></p>
<p>     May suppress reactions to skin tests</p>
<p>     Burning or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, especially in the perineal area (after IV injection)</p>
<p>     Other cutaneous reactions, such as <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span></p>
<p>Neurologic:</p>
<p>     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually after treatment</p>
<p>     <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Psychic disturbances</span></p>
<p>Endocrine:</p>
<p>     Menstrual irregularities</p>
<p>     Development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state</p>
<p>     Suppression of growth in children</p>
<p>     Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness</p>
<p>     Decreased carbohydrate tolerance</p>
<p>     Manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus</p>
<p>     Increased requirements for insulin or oral hypoglycemic agents in diabetics</p>
<p>     <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></p>
<p>Ophthalmic:</p>
<p>     <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">Posterior subcapsular cataracts</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span></p>
<p>Metabolic:</p>
<p>     Negative nitrogen balance due to protein catabolism</p>
<p>Cardiovascular:</p>
<p>     <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">Myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (see <span class="Bold"><span class="Emphasis"><a href="#e1fe72ea-c1c2-4505-a680-6a0dbf0004e0">WARNINGS</a></span></span>)</p>
<p>Other:</p>
<p>     Anaphylactoid or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span></p>
<p>     The following additional adverse reactions are related to parenteral corticosteroid therapy:</p>
<p>     Rare instances of <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> associated with intralesional therapy around the face and head</p>
<p>     Hyperpigmentation or hypopigmentation</p>
<p>     Subcutaneous and cutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span></p>
<p>     Sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span></p>
<p>     Post-injection flare (following intra-articular use)</p>
<p>     Charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>Reports of acute toxicity and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> following overdosage of glucocorticoids are rare.  In the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic.</p>
<p>The oral LD<span class="Sub">50</span> of dexamethasone in female mice was 6.5 g/kg.  The intravenous LD<span class="Sub">50</span> of dexamethasone sodium phosphate in female mice was 794 mg/kg.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Dexamethasone sodium phosphate injection, 4 mg/mL – <span class="Italics"><span class="Emphasis">For intravenous, intramuscular, intra-articular, intralesional, and soft tissue injection.</span></span></p>
<p>Dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to Sodium Chloride Injection or Dextrose Injection and administered by intravenous drip.</p>
<p>Solutions used for intravenous administration or further dilution of this product should be preservative free when used in the neonate, especially the premature infant.</p>
<p>When it is mixed with an infusion solution, sterile precautions should be observed.  Since infusion solutions generally do not contain preservatives, mixtures should be used within 24 hours.</p>
<p><span class="Bold"><span class="Emphasis">DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.</span></span></p>
<p>
 
</p>
<p></p>
<p>The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated.  In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required.</p>
<p>The initial dosage should be maintained or adjusted until the patient’s response is satisfactory.  If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy.</p>
<p>After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.</p>
<p>Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>).  During stress it may be necessary to increase dosage temporarily.</p>
<p>If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.</p>
<p>When the intravenous route of administration is used, dosage usually should be the same as the oral dosage.  In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.  The slower rate of absorption by intramuscular administration should be recognized.</p>
<p>
 
</p>
<p></p>
<p>There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.  The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span><span class="Emphasis">Author </span></span></p></td>
<td><p class="First"><span><span class="Emphasis"> Dosage</span></span></p></td>
</tr>
<tr>
<td><p class="First">Cavanagh<span class="Sup">1</span></p></td>
<td><p class="First">3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg</p></td>
</tr>
<tr>
<td><p class="First">Dietzman<span class="Sup">2</span></p></td>
<td><p class="First">2 to 6 mg/kg of body weight as a single intravenous injection</p></td>
</tr>
<tr>
<td><p class="First">Frank<span class="Sup">3</span></p></td>
<td>
<p class="First">40 mg initially followed by repeat</p>
<p>intravenous injection every 4 to 6 hours while <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> persists</p>
</td>
</tr>
<tr>
<td><p class="First">Oaks<span class="Sup">4</span></p></td>
<td>
<p class="First">40 mg initially followed by repeat</p>
<p>intravenous injection every 2 to 6 hours while <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> persists</p>
</td>
</tr>
<tr class="Last">
<td><p class="First">Schumer<span class="Sup">5</span></p></td>
<td><p class="First">1 mg/kg of body weight as a single intravenous injection</p></td>
</tr>
</tbody></table>
<p>Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours.</p>
<p>Although adverse reactions associated with high dose, short term corticosteroid therapy are uncommon, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> may occur.</p>
<p>
 
</p>
<p></p>
<p>Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> subside.  Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days.  For palliative management of patients with recurrent or inoperable <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumors</span>, maintenance therapy with two mg two or three times a day may be effective.</p>
<p>
 
</p>
<p></p>
<p>In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested:</p>
<p>Dexamethasone sodium phosphate injection, 4 mg/mL: first day, 1 or 2 mL (4 or 8 mg), intramuscularly.</p>
<p>Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day, 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit.</p>
<p>This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.</p>
<p>
 
</p>
<p></p>
<p>Intra-articular, intralesional, and soft tissue injections are generally employed when the affected joints or areas are limited to one or two sites.  Dosage and frequency of injection varies depending on the condition and the site of injection.  The usual dose is from 0.2 to 6 mg.  The frequency usually ranges from once every three to five days to once every two to three weeks.  Frequent intra-articular injection may result in damage to joint tissues.</p>
<p>Some of the usual single doses are: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold"><span class="Emphasis">Site of Injection</span></span></p></td>
<td>
<p class="First"><span class="Bold"><span class="Emphasis">Amount of</span></span></p>
<p><span class="Bold"><span class="Emphasis">Dexamethasone</span></span></p>
<p><span class="Bold"><span class="Emphasis">Phosphate (mg)</span></span></p>
</td>
</tr>
<tr>
<td>
<p class="First">Large Joints</p>
<p>(e.g., Knee)</p>
</td>
<td><p class="First">2 to 4</p></td>
</tr>
<tr>
<td>
<p class="First">Small Joints</p>
<p>(e.g., Interphalangeal,</p>
<p>Temporomandibular)</p>
</td>
<td><p class="First">0.8 to 1</p></td>
</tr>
<tr>
<td><p class="First">Bursae</p></td>
<td><p class="First">2 to 3</p></td>
</tr>
<tr>
<td><p class="First">Tendon Sheaths</p></td>
<td><p class="First">0.4 to 1</p></td>
</tr>
<tr>
<td><p class="First">Soft Tissue Infiltration</p></td>
<td><p class="First">2 to 6</p></td>
</tr>
<tr class="Last">
<td><p class="First">Ganglia</p></td>
<td><p class="First">1 to 2</p></td>
</tr>
</tbody></table>
<p>Dexamethasone sodium phosphate injection is particularly recommended for use in conjunction with one of the less soluble, longer-acting steroids for intra-articular and soft tissue injection.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<table><tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Bold"><span class="Emphasis">Product </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td>
<p class="First"><span class="Bold"><span class="Emphasis">NDC </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td><p class="First"> </p></td>
</tr>
<tr>
<td><p class="First">16501</p></td>
<td><p class="First">63323-165-01</p></td>
<td><p class="First">Dexamethasone Sodium Phosphate Injection, USP (equivalent to dexamethasone phosphate 4 mg/mL) 2 mL flip-top vials packaged in 25.</p></td>
</tr>
<tr>
<td><p class="First">16505</p></td>
<td><p class="First">63323-165-05</p></td>
<td><p class="First">Dexamethasone Sodium Phosphate Injection, USP (equivalent to dexamethasone phosphate 4 mg/mL) 5 mL flip-top vials packaged in 25.</p></td>
</tr>
<tr class="Last">
<td><p class="First">16530</p></td>
<td><p class="First">63323-165-30</p></td>
<td><p class="First">Dexamethasone Sodium Phosphate Injection, USP (equivalent to dexamethasone phosphate 4 mg/mL) 30 mL flip-top vials packaged individually.</p></td>
</tr>
</tbody></table>
<p>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].  Protect from freezing.  Sensitive to heat.  Do not autoclave.<br>
 <br>
Protect from light. Store container in carton until contents have been used.<br>
 <br>
Do not use if precipitate is present.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"></p>
<ol>
<li>Cavanagh, D.; Singh, K.B.: Endotoxin <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> in pregnancy and abortion, in: “Corticosteroids in the Treatment of Shock?, Schumer, W.; Nyhus, L.M., Editors, Urbana, University of Illinois Press, 1970, pp. 86-96.</li>
<li>Dietzman, R.H.; Ersek, R.A.; Bloch, J.M.; Lillehei, R.C.: High-output, low-resistance gram-negative <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> in man, Angiology 20: 691-700, Dec. 1969.</li>
<li>Frank, E.: Clinical observations in <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and management (In: Shields, T.F., ed.: Symposium on current concepts and management of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), J. Maine Med. Ass. 59: 195-200, Oct. 1968.</li>
<li>Oaks, W. W.; Cohen, H.E.: Endotoxin <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> in the geriatric patient, Geriat. 22: 120-130, Mar. 1967.</li>
<li>Schumer, W.; Nyhus, L.M.: Corticosteroid effect on biochemical parameters of human oligemic <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, Arch. Surg. 100: 405-408, Apr. 1970.</li>
</ol>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=685c33e5-c6e0-4717-b3bb-4c2cd0fcb063&amp;name=MM2.jpg"> </p>
<p>45799E</p>
<p>Revises: January 2008</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Dexamethasone Sodium Phosphate </p>
<p><br></p>
<p>GENERIC: DEXAMETHASONE SODIUM PHOSPHATE</p>
<p><br></p>
<p>DOSAGE: INJECTION, SOLUTION</p>
<p><br></p>
<p>ADMINSTRATION: INTRAMUSCULAR</p>
<p><br></p>
<p>NDC: 49349-841-41</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>DEXAMETHASONE SODIUM PHOSPHATE 4mg in 1mL</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>BENZYL ALCOHOL</li>
<li>SODIUM HYDROXIDE</li>
<li>CITRIC ACID MONOHYDRATE</li>
<li>SODIUM CITRATE</li>
<li>SODIUM SULFITE</li>
</ul>
<p><br></p>
<p>PACKAGING: 1 mL in 1 VIAL</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=685c33e5-c6e0-4717-b3bb-4c2cd0fcb063&amp;name=MM3.jpg"></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=685c33e5-c6e0-4717-b3bb-4c2cd0fcb063&amp;name=MM4.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEXAMETHASONE SODIUM PHOSPHATE 		
					</strong><br><span class="contentTableReg">dexamethasone sodium phosphate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-841(NDC:63323-165)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXAMETHASONE SODIUM PHOSPHATE</strong> (DEXAMETHASONE) </td>
<td class="formItem">DEXAMETHASONE</td>
<td class="formItem">4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM SULFITE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-841-41</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA084916</td>
<td class="formItem">12/11/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>05548b30-f1fc-42d4-b99c-c66e9c594eb7</div>
<div>Set id: 685c33e5-c6e0-4717-b3bb-4c2cd0fcb063</div>
<div>Version: 4</div>
<div>Effective Time: 20131211</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
